Pilot Study of Neurovision to Improve Vision and Slow Myopia Progression in Children With Myopia
NCT ID: NCT00348218
Last Updated: 2010-05-12
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2006-06-30
Study Completion Date
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a pilot study to assess the effectiveness of Neurovision treatment in the improvement of vision in children being under-corrected and to assess the effectiveness of Neurovision treatment in slowing down myopia progression in children.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Singapore Pilot Study to Assess Neurovision in Treatment of Low Myopia
NCT00348127
Myopia
COMPLETED
PHASE1
A Singapore Study to Assess How Neurovision Improve the Vision of Adults With Low to Moderate Myopia
NCT00348075
Myopia
COMPLETED
NA
Evaluating NeuroVision's Neural Vision Correction (NVC) Myopia Treatment
NCT00469612
Myopia
TERMINATED
NA
Pilot Study to Assess the Efficacy of Short Exposure to Defocus to Slow the Progression of Myopia in Children
NCT00400140
Myopia
COMPLETED
NA
Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old
NCT00315198
Amblyopia
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
NeuroVision's NVC vision correction technology is a non-invasive, patient-specific computerized treatment based on visual stimulation and facilitation of neural connections responsible for vision. NeuroVision's Neural Vision Correction TM (NVC) technology has been developed through research focused solely on optimizing performance of the neural or "back end" of the visual system, and is based on two decades of visual neuroscience research by the founder, Dr Uri Polat, whose work, which has been published in leading scientific journals, relates to understanding how the brain processes visual information, how neural activity is related to visual perception, and how visual processing interacts with other neural systems.
The technology has been clinically proven in the treatment of adult amblyopia, which until now has been considered untreatable, with a RCT in which follow-up of up to 2 years shows good retention of visual improvement. The company has received FDA 510(k) marketing clearance indicating NVC for the treatment of adult amblyopia in patients 9 years or older in the US. The company also received a Medical CE-Mark to market its Amblyopia and Low-Myopia products in the European Union. Company products are also approved for use in Israel by the Israeli Ministry of Health - Device License Authority. Additional proof-of-concept studies have been performed in Israel and Singapore indicating the technology's potential to improve vision of subjects having low myopia.
Today, NeuroVision commercially offers the Low Myopia treatment in Singapore. Initial results of the commercial treatment are even better than the proof-of-concept studies, emphasizing the importance of patient motivation and compliance in this treatment.
Based on the promising results of the Low Myopia treatment in adults, this study intends to evaluate the efficacy of NVC treatment in myopic children, by improving their quality of vision and reducing the progress rate of their Myopia.
The first objective of this study is to evaluate the improvement of visual acuity in children being under-corrected. As the myopia increases rapidly in many children, their habitual eyewear cannot match their exact degree of myopia on a day by day basis. As a result, many children suffer from reduced quality of vision (as shown also in data from the Singapore Cohort Study of the Risk Factors of Myopia \[SCORM\] study). Therefore, the first goal of this study is to evaluate the effectiveness of NeuroVision treatment in the improvement of the under-corrected visual acuity of these children.
The second objective is to evaluate the effectiveness of NeuroVision treatment in the reduction of the myopia progression rate in children. As detailed later on in this document, studies on animals showed that under-correcting myopia can reduce its progression rate (or even result in emmetropization). Therefore, the second goal of this study is to evaluate the possibility of significantly under-correcting myopia in children that had undergone NeuroVision treatment, and check how it affects the progression of their myopia.
To achieve the above objectives, a large scale (few hundred subjects) clinical study on school children, is required. This pilot study is designed to examine the feasibility of such a large scale study, from clinical, administrative and logistic points of view.
Treatment flow and process
The treatment flow is composed of the following phases
1. Screening and Enrollment
The Screening Evaluation phase includes the following steps:
1. Demographic details
2. General medical history
3. Baseline Examination I. Manifest Subjective and Objective refraction II. Accommodation amplitude, PRA and NRA III. Distance visual acuity (Monocular and binocular Under-corrected Visual Acuity, and Best Corrected Visual Acuity - BCVA) IV. Cycloplegic Objective and Subjective refraction V. Distance cycloplegic under-corrected visual acuity. VI. Ocular axial length measurements
For detailed description of the above examinations, refer to Appendices A-B.
After the completion of all the required examinations, subject's data will be reviewed and study investigators make a final enrolment decision.
Before starting the computerized evaluations, subjects will undergo an additional Distance Visual Acuity and Contrast Sensitivity examinations at the school.
The results of these additional examinations will be used as a baseline reference for the periodic examinations that will be done during the treatment period.
Enrolled Subjects will be requested to complete a QOV/QOL Questionnaire 1 (Annex E) before the treatment starts
2. NVC Computerized Evaluation
The Computerized Evaluation sessions are conducted in order to allow the NVC system to identify the visual abilities and inefficiencies and to thereby define individual parameters that will affect the subject's treatment plan.
This phase is comprised of two (2) to three (3) sessions.
Training Glasses:
NeuroVision will determine the power of the training eyeglasses the subject will need for the NVC treatment start. The possible training glasses are 0.5DS, 1.0DS or 1.5DS less than the subject's full prescription. In some cases, there will be no training glasses.
In some cases a subject might be instructed to train one eye only for a part of the treatment sessions. The other eye will be then covered by a semi-translucent lens.
The decisions are made by NeuroVision based on the subject's best refractive correction, his/her under-corrected VA and the computerized evaluation, and will be reported to the study coordinator.
3. NVC Treatment
The total number of sessions to complete the treatment course is not defined in advance. It is determined by the NVC system during the course of treatment according to each subject's visual abilities and performance. Typically patient should undergo 30 sessions during this phase.
The subject should perform on average three (3) sessions per week.
During this phase no visit interruptions longer than two (2) weeks on aggregate are permitted.
Periodic visual acuity and contrast sensitivity examinations should be performed after every 5 treatment sessions in the school
As progress is made, the training glasses previously provided to the subject may be replaced by other training glasses with less power, or entirely removed. The clinician and the subject will be informed about the training glass replacement in advance.
After completing 15 treatment sessions (mid-term), subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F) before commencing Treatment Session 16.
NOTE:
WHEN VA TEST AND THE TREATMENT SESSION ARE TO BE PERFORMED AT THE SAME VISIT, PERIODIC VA TESTS SHOULD BE ALWAYS CONDUCTED BEFORE THE PERFORMANCE OF A TREATMENT SESSION!
4. End of Treatment Decision
Subject will terminate the treatment sequence according to the end of treatment criteria (see summary of study design)
Following the end of Treatment decision, the subject should be scheduled for Post Treatment Examinations (PTE) within 2 weeks.
For follow up visits, visit range allowed is within +/- two weeks of the expected dates
5. Post Treatment Examination (PTE)
The Post Treatment Examination at SERI will include visual acuity tests, amplitude of accommodation, relative accommodation, cover test, cycloplegic refraction and distance under-corrected visual acuity and axial length measurement.
Subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F)
6. Prescription of under-corrected eyewear
After the end of the treatment, subjects should be prescribed with under-corrected eyewear.
The under-corrected eyewear should be the lowest possible refractive correction in which that subject has at least 6/12 (0.3 LogMAR) binocular VA.
The subject should be instructed to use the new eyewear instead of the current one (if any) for at least the 12 months monitoring period.
7. Follow-Up Examinations at Months 3, 6, 9 and 12
Follow-Up Examinations at Months 3, 6, 9 and 12 post treatment at SERI will include visual acuity tests, amplitude of accommodation, relative accommodation, cover test, cycloplegic refraction and distance under-corrected visual acuity.
In case that the subject's binocular VA with the under-corrected eyewear is worse than 6/12 (0.3 LogMAR) for 2 consecutive follow-up visits, new eyewear should be prescribed to allow at least 6/12 binocular VA.
At Follow up Month 6 and 12, subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F)."
The technology has been clinically proven in the treatment of adult amblyopia, which until now has been considered untreatable, with a RCT in which follow-up of up to 2 years shows good retention of visual improvement. The company has received FDA 510(k) marketing clearance indicating NVC for the treatment of adult amblyopia in patients 9 years or older in the US. The company also received a Medical CE-Mark to market its Amblyopia and Low-Myopia products in the European Union. Company products are also approved for use in Israel by the Israeli Ministry of Health - Device License Authority. Additional proof-of-concept studies have been performed in Israel and Singapore indicating the technology's potential to improve vision of subjects having low myopia.
Today, NeuroVision commercially offers the Low Myopia treatment in Singapore. Initial results of the commercial treatment are even better than the proof-of-concept studies, emphasizing the importance of patient motivation and compliance in this treatment.
Based on the promising results of the Low Myopia treatment in adults, this study intends to evaluate the efficacy of NVC treatment in myopic children, by improving their quality of vision and reducing the progress rate of their Myopia.
The first objective of this study is to evaluate the improvement of visual acuity in children being under-corrected. As the myopia increases rapidly in many children, their habitual eyewear cannot match their exact degree of myopia on a day by day basis. As a result, many children suffer from reduced quality of vision (as shown also in data from the Singapore Cohort Study of the Risk Factors of Myopia \[SCORM\] study). Therefore, the first goal of this study is to evaluate the effectiveness of NeuroVision treatment in the improvement of the under-corrected visual acuity of these children.
The second objective is to evaluate the effectiveness of NeuroVision treatment in the reduction of the myopia progression rate in children. As detailed later on in this document, studies on animals showed that under-correcting myopia can reduce its progression rate (or even result in emmetropization). Therefore, the second goal of this study is to evaluate the possibility of significantly under-correcting myopia in children that had undergone NeuroVision treatment, and check how it affects the progression of their myopia.
To achieve the above objectives, a large scale (few hundred subjects) clinical study on school children, is required. This pilot study is designed to examine the feasibility of such a large scale study, from clinical, administrative and logistic points of view.
Treatment flow and process
The treatment flow is composed of the following phases
1. Screening and Enrollment
The Screening Evaluation phase includes the following steps:
1. Demographic details
2. General medical history
3. Baseline Examination I. Manifest Subjective and Objective refraction II. Accommodation amplitude, PRA and NRA III. Distance visual acuity (Monocular and binocular Under-corrected Visual Acuity, and Best Corrected Visual Acuity - BCVA) IV. Cycloplegic Objective and Subjective refraction V. Distance cycloplegic under-corrected visual acuity. VI. Ocular axial length measurements
For detailed description of the above examinations, refer to Appendices A-B.
After the completion of all the required examinations, subject's data will be reviewed and study investigators make a final enrolment decision.
Before starting the computerized evaluations, subjects will undergo an additional Distance Visual Acuity and Contrast Sensitivity examinations at the school.
The results of these additional examinations will be used as a baseline reference for the periodic examinations that will be done during the treatment period.
Enrolled Subjects will be requested to complete a QOV/QOL Questionnaire 1 (Annex E) before the treatment starts
2. NVC Computerized Evaluation
The Computerized Evaluation sessions are conducted in order to allow the NVC system to identify the visual abilities and inefficiencies and to thereby define individual parameters that will affect the subject's treatment plan.
This phase is comprised of two (2) to three (3) sessions.
Training Glasses:
NeuroVision will determine the power of the training eyeglasses the subject will need for the NVC treatment start. The possible training glasses are 0.5DS, 1.0DS or 1.5DS less than the subject's full prescription. In some cases, there will be no training glasses.
In some cases a subject might be instructed to train one eye only for a part of the treatment sessions. The other eye will be then covered by a semi-translucent lens.
The decisions are made by NeuroVision based on the subject's best refractive correction, his/her under-corrected VA and the computerized evaluation, and will be reported to the study coordinator.
3. NVC Treatment
The total number of sessions to complete the treatment course is not defined in advance. It is determined by the NVC system during the course of treatment according to each subject's visual abilities and performance. Typically patient should undergo 30 sessions during this phase.
The subject should perform on average three (3) sessions per week.
During this phase no visit interruptions longer than two (2) weeks on aggregate are permitted.
Periodic visual acuity and contrast sensitivity examinations should be performed after every 5 treatment sessions in the school
As progress is made, the training glasses previously provided to the subject may be replaced by other training glasses with less power, or entirely removed. The clinician and the subject will be informed about the training glass replacement in advance.
After completing 15 treatment sessions (mid-term), subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F) before commencing Treatment Session 16.
NOTE:
WHEN VA TEST AND THE TREATMENT SESSION ARE TO BE PERFORMED AT THE SAME VISIT, PERIODIC VA TESTS SHOULD BE ALWAYS CONDUCTED BEFORE THE PERFORMANCE OF A TREATMENT SESSION!
4. End of Treatment Decision
Subject will terminate the treatment sequence according to the end of treatment criteria (see summary of study design)
Following the end of Treatment decision, the subject should be scheduled for Post Treatment Examinations (PTE) within 2 weeks.
For follow up visits, visit range allowed is within +/- two weeks of the expected dates
5. Post Treatment Examination (PTE)
The Post Treatment Examination at SERI will include visual acuity tests, amplitude of accommodation, relative accommodation, cover test, cycloplegic refraction and distance under-corrected visual acuity and axial length measurement.
Subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F)
6. Prescription of under-corrected eyewear
After the end of the treatment, subjects should be prescribed with under-corrected eyewear.
The under-corrected eyewear should be the lowest possible refractive correction in which that subject has at least 6/12 (0.3 LogMAR) binocular VA.
The subject should be instructed to use the new eyewear instead of the current one (if any) for at least the 12 months monitoring period.
7. Follow-Up Examinations at Months 3, 6, 9 and 12
Follow-Up Examinations at Months 3, 6, 9 and 12 post treatment at SERI will include visual acuity tests, amplitude of accommodation, relative accommodation, cover test, cycloplegic refraction and distance under-corrected visual acuity.
In case that the subject's binocular VA with the under-corrected eyewear is worse than 6/12 (0.3 LogMAR) for 2 consecutive follow-up visits, new eyewear should be prescribed to allow at least 6/12 binocular VA.
At Follow up Month 6 and 12, subjects will be requested to complete a QOV/QOL Questionnaire 2 (Annex F)."
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Myopia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NeuroVision
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. The subject's age is between 7 to 9 years.
2. The subject's cycloplegic refraction is at least -1.0DS in either eye.
3. The subject's manifest spherical equivalence does not differ by more than 1.0 D from cycloplegic spherical equivalence
4. The subject's visual acuity with an under correction of 1DS (compared to the manifest subjective VA), in both eyes, should not exceed 0.6 LogMAR.
5. The subject's best corrected visual acuity 0.04 LogMAR (either eye)
6. The subject is cognitively intact and is able to follow multiple step instructions.
7. The subject and his parents/legal guardians are very keen to improve the habitual visual acuity and to reduce the progression rate of myopia
8. The subject is able and willing to attend all study sessions and visits at the required frequency:
* The total number of treatments is individual, approximately 30 and no more than 40.
* The required pace for the treatment sessions is at least 3 sessions per week.
* No foreseen interruptions longer than 2 weeks during the treatment course.
9. The subject is able to cease contact lens wear from Baseline examination onwards until the end of the treatment period (phase I).
10. The subject's parent/legal guardian agrees to sign the Informed Consent Form (See Appendix D)
11. Subject's parent/legal guardian agrees to follow the study instruction including use of optical aids
2. The subject's cycloplegic refraction is at least -1.0DS in either eye.
3. The subject's manifest spherical equivalence does not differ by more than 1.0 D from cycloplegic spherical equivalence
4. The subject's visual acuity with an under correction of 1DS (compared to the manifest subjective VA), in both eyes, should not exceed 0.6 LogMAR.
5. The subject's best corrected visual acuity 0.04 LogMAR (either eye)
6. The subject is cognitively intact and is able to follow multiple step instructions.
7. The subject and his parents/legal guardians are very keen to improve the habitual visual acuity and to reduce the progression rate of myopia
8. The subject is able and willing to attend all study sessions and visits at the required frequency:
* The total number of treatments is individual, approximately 30 and no more than 40.
* The required pace for the treatment sessions is at least 3 sessions per week.
* No foreseen interruptions longer than 2 weeks during the treatment course.
9. The subject is able to cease contact lens wear from Baseline examination onwards until the end of the treatment period (phase I).
10. The subject's parent/legal guardian agrees to sign the Informed Consent Form (See Appendix D)
11. Subject's parent/legal guardian agrees to follow the study instruction including use of optical aids
Exclusion Criteria
1. The subject suffers from any other eye disease(s) or other causes for the reduced visual acuity, aside from myopia and/or astigmatism.
2. The subject suffers from myopia-related visual complications resulting in visual loss, including myopic macular degeneration, myopic cataract and previous or pre-existing myopic retinal detachment.
3. The subject is suffering from Diabetes Mellitus.
4. The subject suffers from binocular vision problems, such as high exophoria / divergent squint / nystagmus
5. The subject has an activity limitation due to medical disorders (including migraines, seizure disorders, etc.), medications, or emotional status that might potentially impair the subject's ability to perform the treatment.
2. The subject suffers from myopia-related visual complications resulting in visual loss, including myopic macular degeneration, myopic cataract and previous or pre-existing myopic retinal detachment.
3. The subject is suffering from Diabetes Mellitus.
4. The subject suffers from binocular vision problems, such as high exophoria / divergent squint / nystagmus
5. The subject has an activity limitation due to medical disorders (including migraines, seizure disorders, etc.), medications, or emotional status that might potentially impair the subject's ability to perform the treatment.
Minimum Eligible Age
7 Years
Maximum Eligible Age
9 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NeuroVision
INDUSTRY
Sponsor Role
collaborator
Health Promotion Board, Singapore
OTHER_GOV
Sponsor Role
collaborator
Singapore National Eye Centre
OTHER_GOV
Sponsor Role
lead
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donald Tan, FRCS
Role: PRINCIPAL_INVESTIGATOR
Singapore Eye Research Institute
Wei Han Chua, FRCS
Role: PRINCIPAL_INVESTIGATOR
Singapore National Eye Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Singapore Eye Research Institute
Singapore, , Singapore
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Singapore
References
Explore related publications, articles, or registry entries linked to this study.
Polat U, Ma-Naim T, Belkin M, Sagi D. Improving vision in adult amblyopia by perceptual learning. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6692-7. doi: 10.1073/pnas.0401200101. Epub 2004 Apr 19.
Reference Type
BACKGROUND
Lim KL, Fam HB. NeuroVision treatment for low myopia following LASIK regression. J Refract Surg. 2006 Apr;22(4):406-8. doi: 10.3928/1081-597X-20060401-20.
Reference Type
BACKGROUND
Polat U, Mizobe K, Pettet MW, Kasamatsu T, Norcia AM. Collinear stimuli regulate visual responses depending on cell's contrast threshold. Nature. 1998 Feb 5;391(6667):580-4. doi: 10.1038/35372.
Reference Type
BACKGROUND
Levi DM, Polat U, Hu YS. Improvement in Vernier acuity in adults with amblyopia. Practice makes better. Invest Ophthalmol Vis Sci. 1997 Jul;38(8):1493-510.
Reference Type
BACKGROUND
Polat U, Norcia AM. Neurophysiological evidence for contrast dependent long-range facilitation and suppression in the human visual cortex. Vision Res. 1996 Jul;36(14):2099-109. doi: 10.1016/0042-6989(95)00281-2.
Reference Type
BACKGROUND
Sagi D, Tanne D. Perceptual learning: learning to see. Curr Opin Neurobiol. 1994 Apr;4(2):195-9. doi: 10.1016/0959-4388(94)90072-8.
Reference Type
BACKGROUND
Polat U, Sagi D. Spatial interactions in human vision: from near to far via experience-dependent cascades of connections. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1206-9. doi: 10.1073/pnas.91.4.1206.
Reference Type
BACKGROUND
Polat U, Sagi D. Lateral interactions between spatial channels: suppression and facilitation revealed by lateral masking experiments. Vision Res. 1993 May;33(7):993-9. doi: 10.1016/0042-6989(93)90081-7.
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
http://www.seri.com.sg/
Singapore Eye Research Institute Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R462/11/2006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Exploring Perceptual Learning in Blurred Gabor Discrimination for Low-Myopic Children
NCT07107646
ENROLLING_BY_INVITATION
NA
Comparative Study of Cycloplegic Refraction and Subjective Refraction With Fogging in School Age Children
NCT00347347
COMPLETED
Brain Visual Perception Training for Prevention and Control of Premyopia
NCT06585657
NOT_YET_RECRUITING
NA
Exploratory Study on the Effectiveness of Myopia Control Lenses in Slowing Myopia Progression in Young Children
NCT06857864
ACTIVE_NOT_RECRUITING
NA
Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?
NCT00348166
WITHDRAWN
PHASE1
Clinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression
NCT06850168
RECRUITING
NA
The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens
NCT05886348
ACTIVE_NOT_RECRUITING
NA
Red Light Intervention on Myopic Progression
NCT05203432
UNKNOWN
NA
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
RECRUITING
PHASE3
Virtual Far-sight Reading Device for Myopia Intervention Among Pre-myopic Children
NCT06995911
NOT_YET_RECRUITING
NA
Real-World Study of Myopia Prevention and Control in Children
NCT06849895
NOT_YET_RECRUITING
Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children
NCT00371124
UNKNOWN
PHASE2/PHASE3
Influence of Rodenstock Spectacle Lenses on Myopia Progression.
NCT06816446
RECRUITING
NA
The Health-Related Quality of Life of the Patients With Symptomatic Convergence Insufficiency
NCT05948046
UNKNOWN
Pilot Study of Accommodative/Vergence Therapy to Modify Accommodative Function in Children With Myopia
NCT02578407
UNKNOWN
NA
Myopia Control: a Comparison Study Between Atropine and MiSight
NCT05815784
RECRUITING
PHASE2
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression
NCT05331378
ACTIVE_NOT_RECRUITING
NA
An Evaluation of Treatment of Amblyopia in Children 7 To <18 Years Old
NCT00094692
COMPLETED
PHASE3
Low-Dose Atropine for Treatment of Myopia
NCT03334253
COMPLETED
PHASE3
Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens
NCT06034327
RECRUITING
NA
Amblyopia (Lazy Eye) Treatment Study
NCT00001864
COMPLETED
PHASE3
Treatment for Amblyopia Under Binocular Conditions Versus the Standard of Care, Monocular Deprivation Treatment
NCT05185076
UNKNOWN
NA
Effectiveness of Virtual Reality Training in Amblyopia
NCT05732467
UNKNOWN
NA
Observational Study of Optical Correction for Strabismic Amblyopia in Children 3 to <7 Years Old
NCT00669539
COMPLETED
Assessment of Device for Treatment of Amblyopia
NCT02003235
COMPLETED
NA